Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.
Saved in:
| Title: | Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial. |
|---|---|
| Authors: | Wu, Chao1 (AUTHOR), Niu, Xuping2 (AUTHOR), Wang, Xiaohua3 (AUTHOR), Su, Juan4 (AUTHOR), Zhao, Hengguang5 (AUTHOR), Lin, Mao6 (AUTHOR), Yang, Chunjun7 (AUTHOR), Qin, Xiaoming8 (AUTHOR), Guo, Shuping9 (AUTHOR), Jiang, Cunhuo10 (AUTHOR), Tang, Hui11 (AUTHOR), Yang, Haijing11 (AUTHOR), Wu, Liming12 (AUTHOR), Zhu, Min13 (AUTHOR), Wei, Aihua14 (AUTHOR), Tao, Xiaohua15 (AUTHOR), Zhang, Yiwen15 (AUTHOR), Shu, Chang1 (AUTHOR), Liu, Jiawei1 (AUTHOR), Yang, Lu1 (AUTHOR) |
| Source: | Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3431-3443. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
